Author [ Title] Type Year
Filters: Author is Kebriaei, Partow [Clear All Filters]
Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015.
Age is a prognostic factor for the overall survival of multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant. 2018.
Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv. 2020;4(19):4834-4837.
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage. Cancer. 2018.
Chimeric Antigen Receptor T-cell Therapy Toxicities. Br J Clin Pharmacol. 2020..
Chimeric Antigen Receptor Therapy: How Are We Driving in Solid Tumors?. Biol Blood Marrow Transplant. 2020..
Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Adv. 2020;4(13):3123-3127.
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2019.
Clinical utilization of Chimeric Antigen Receptors T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL) - an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transpl. Biol Blood Marrow Transplant. 2018.
Detection of MRD may predict the outcome of patients with Philadelphia-chromosome positive ALL treated with tyrosine kinase inhibitors plus chemotherapy. Blood. 2013.
Haploidentical Hematopoietic Stem Cell Transplantation as Platform for Post-transplant Cellular Therapy. Biol Blood Marrow Transplant. 2015..
Haploidentical Transplantation for Acute Myeloid Leukemia Patients with Minimal/ Measurable Residual Disease at Transplantation. Am J Hematol. 2019.
Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019.
Impact of Donor Type and Melphalan Dose on Allogeneic Transplant Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019.
Manufacture of Clinical-Grade CD19-Specific T Cells Stably Expressing Chimeric Antigen Receptor Using Sleeping Beauty System and Artificial Antigen Presenting Cells. PLoS One. 2013;8(5):e64138.
Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol. 2018.
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia. Br J Haematol. 2015.